Evidence map›Paper›PMID 28191909›Full record

ReviewClinical cardiology2017

The influence of chemotherapy on the right ventricle: did we forget something?

Marijana Tadic, Cesare Cuspidi, Dagmara Hering, Lucia Venneri, Oleksandr Danylenko

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Chemotherapy-Induced Right Ventricular Dysfunction.Medicina (Kaunas, Lithuania) · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Standardisation and future of preclinical echocardiography.Mammalian genome : official journal of the International Mammalian Genome Society · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Right ventricular function during trastuzumab therapy for breast cancer.The international journal of cardiovascular imaging · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Marijana TadicCardiology department, University Clinical Hospital Centre "Dr. Dragisa Misovic", Belgrade, Serbia.ORCID http://orcid.org/0000-0002-6235-5152
Cesare CuspidiClinical Research Unit, University of Milan-Bicocca and Italian Institute for Auxology, Meda, Italy.
Dagmara HeringDobney Hypertension Centre, School of Medicine and Pharmacology-Royal Perth, Hospital Unit, The University of Western Australia, Perth, Australia.
Lucia VenneriDepartment of Echocardiography, Royal Brompton Hospital, London, United Kingdom.
Oleksandr DanylenkoDepartment of Echocardiography, Royal Brompton Hospital, London, United Kingdom.
Royal Brompton Hospital · GBThe University of Western Australia · AUUniversity Hospital Center Dr Dragiša Mišović · RSUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA large number of chemotherapy-induced cardiovascular complications were discovered in studies over the last several decades. The focus of the majority of these studies was left ventricular (LV) remodeling. The aim of this article was to provide a comprehensive overview of potential mechanisms of chemotherapy-induced right ventricular (RV) remodeling and summarize clinical studies on this topic. HYPOTHESIS: Chemotherapy induces RV structural, functional, and mechanical changes.

methodsWe searched PubMed, MEDLINE, Ovid and Embase databases for studies published from January 1990 up to September 2016 in the English language using the following keyword "chemotherapy," "heart," "right ventricle," "anthracyclines," and "trastuzumab."

resultsThe existing research show that RV remodeling occurs simultaneously with LV remodeling, which is why RV remodeling should not be neglected in the overall cardiac assessment of patients treated with chemotherapy, and especially those protocols that involve anthracyclines and trastuzumab. Investigations showed that these agents could significantly impact RV structure, function, and mechanics. These medications induce fibrosis of the RV myocardium, RV dilatation, decline in RV systolic function, worsening of its diastolic function, and finally impairment of RV mechanics (strain). The mechanisms of chemotherapy-induced RV remodeling are still not entirely clear, but it is considered that direct destructive influence of chemotherapy on myocardium, oxidative stress, endothelial dysfunction, and negative impact on pulmonary circulation could significantly contribute to RV impairment.

conclusionsChemotherapy induces the impairment of RV structure, function, and mechanics by different complex mechanisms.

Indexed as

Heart FailureHeart VentriclesVentricular Dysfunction, RightAntineoplastic AgentsDiastoleEchocardiographyHumansNeoplasmsStroke VolumeSystoleVentricular Function, RightVentricular RemodelingAntineoplastic Agentscancerchemotherapyright ventricle

Identifiers

PMID28191909
PMCPMC6490398
OpenAlexW2588288439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.